Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Get Free Report) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 24,355 shares, a growth of 465.6% from the July 15th total of 4,306 shares. Approximately 2.4% of the company’s stock are sold short. Based on an average daily trading volume, of 9,824 shares, the days-to-cover ratio is presently 2.5 days.
Institutional Trading of Virtus LifeSci Biotech Products ETF
A hedge fund recently bought a new position in Virtus LifeSci Biotech Products ETF stock. Flow Traders U.S. LLC purchased a new position in shares of Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 7,403 shares of the company’s stock, valued at approximately $431,000. Flow Traders U.S. LLC owned about 1.85% of Virtus LifeSci Biotech Products ETF as of its most recent SEC filing.
Virtus LifeSci Biotech Products ETF Trading Up 0.6%
Shares of NYSEARCA BBP traded up $0.57 during mid-day trading on Wednesday, reaching $102.20. The company had a trading volume of 2,264 shares, compared to its average volume of 8,241. The firm has a 50 day simple moving average of $94.73 and a two-hundred day simple moving average of $87.85. Virtus LifeSci Biotech Products ETF has a 52-week low of $65.68 and a 52-week high of $105.21.
About Virtus LifeSci Biotech Products ETF
The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is managed by Virtus.
Featured Stories
- Five stocks we like better than Virtus LifeSci Biotech Products ETF
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
- TSMC’s 44.7% Sales Surge Signals the AI Boom Is Still Alive
- CoreWeave’s $129 Billion AI Backlog Changes the Bull Case
- Tesla’s Robotaxi Reality Check: Time to Deliver
Receive News & Ratings for Virtus LifeSci Biotech Products ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virtus LifeSci Biotech Products ETF and related companies with MarketBeat.com's FREE daily email newsletter.
